Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Stomach Neoplasms 16Lung Neoplasms 9Neoplasm Metastasis 5Neoplasms 4Adenocarcinoma 4Colonic Neoplasms 3Carcinoma, Hepatocellular 3Thymoma 2Rectal Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1

Interventions

atezolizumab 3Docetaxel 3pembrolizumab 2olaparib 2lenvatinib 2Leucovorin 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorouracil 2Filgrastim 2Capecitabine 2zolbetuximab 1tomivosertib 1spartalizumab 1somatostatin receptor 2 1pralsetinib 1pegylated granulocyte colony-stimulating factor 1necitumumab 1motesanib diphosphate 1ipatasertib 1inavolisib 1entrectinib 1ensartinib 1dapagliflozin 1cobimetinib 1cemiplimab 1cat's claw extract 1balugrastim 1anlotinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × Ramucirumab × Clear all
NCT01634555 2019-02-26

A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI

Eli Lilly and Company

Phase 2 Completed
29 enrolled 12 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡